SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of XBiotech, Inc.

Nov 24, 2015, 11:02 ET from Bronstein, Gewirtz & Grossman, LLC

NEW YORK, Nov. 24, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of XBiotech, Inc. ("XBiotech" or the "Company") (NasdaqGS: XBIT -News).  Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at or 212-697-6484.

The investigation concerns whether XBiotech and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On November 23, 2015, post-market, XBiotech announced that data for 72 patients in its study of True Human(TM) therapeutic antibodies were compromised and are unavailable for primary endpoint evaluation due to irregularities. These irregularities include patients dropping out of the study prior to receiving any dosing with drug or placebo, erroneously receiving either placebo or study drug, and failing to receive scheduled DEXA scans, properly complete EORTC evaluation, or both. 

Following this news, XBiotech stock fell $4.46 or 33.66% during intraday trading to trade at $8.79 on November 24, 2015.

If you are aware of any facts relating to this investigation, or purchased shares of XBiotech, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Eitan Kimelman 212-697-6484


SOURCE Bronstein, Gewirtz & Grossman, LLC